Is there a dark side to long-term proton pump inhibitor therapy?

Thomas B. Nealis, Colin Howden

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Proton pump inhibitors (PPIs) are among the most widely used of prescription drugs. They have revolutionized the management of gastroesophageal reflux disease and other acid-related disorders. Although generally safe, concerns about possible adverse effects continue to arise. Some of these, such as gastric neoplasms, are of theoretical concern only and are related to suppression of gastric acid secretion and consequent hypergastrinemia; these have not been encountered in clinical practice despite millions of patient-years of use. Others are more idiosyncratic, unpredictable, and rare. In general, the therapeutic benefits of PPIs outweigh these potential risks. However, it is important that PPIs are only given for appropriate indications and that, whenever possible, they are used in the lowest effective dose. At present, there is no need for specific monitoring for adverse events during PPI therapy.

Original languageEnglish (US)
Pages (from-to)536-542
Number of pages7
JournalAmerican Journal of Therapeutics
Volume15
Issue number6
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Proton Pump Inhibitors
Prescription Drugs
Gastric Acid
Therapeutics
Gastroesophageal Reflux
Stomach Neoplasms
Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Is there a dark side to long-term proton pump inhibitor therapy? / Nealis, Thomas B.; Howden, Colin.

In: American Journal of Therapeutics, Vol. 15, No. 6, 01.11.2008, p. 536-542.

Research output: Contribution to journalReview article

@article{4c3607c8741b4dc0bcca26f1020fc2e4,
title = "Is there a dark side to long-term proton pump inhibitor therapy?",
abstract = "Proton pump inhibitors (PPIs) are among the most widely used of prescription drugs. They have revolutionized the management of gastroesophageal reflux disease and other acid-related disorders. Although generally safe, concerns about possible adverse effects continue to arise. Some of these, such as gastric neoplasms, are of theoretical concern only and are related to suppression of gastric acid secretion and consequent hypergastrinemia; these have not been encountered in clinical practice despite millions of patient-years of use. Others are more idiosyncratic, unpredictable, and rare. In general, the therapeutic benefits of PPIs outweigh these potential risks. However, it is important that PPIs are only given for appropriate indications and that, whenever possible, they are used in the lowest effective dose. At present, there is no need for specific monitoring for adverse events during PPI therapy.",
author = "Nealis, {Thomas B.} and Colin Howden",
year = "2008",
month = "11",
day = "1",
doi = "10.1097/MJT.0b013e31817149bf",
language = "English (US)",
volume = "15",
pages = "536--542",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Is there a dark side to long-term proton pump inhibitor therapy?

AU - Nealis, Thomas B.

AU - Howden, Colin

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Proton pump inhibitors (PPIs) are among the most widely used of prescription drugs. They have revolutionized the management of gastroesophageal reflux disease and other acid-related disorders. Although generally safe, concerns about possible adverse effects continue to arise. Some of these, such as gastric neoplasms, are of theoretical concern only and are related to suppression of gastric acid secretion and consequent hypergastrinemia; these have not been encountered in clinical practice despite millions of patient-years of use. Others are more idiosyncratic, unpredictable, and rare. In general, the therapeutic benefits of PPIs outweigh these potential risks. However, it is important that PPIs are only given for appropriate indications and that, whenever possible, they are used in the lowest effective dose. At present, there is no need for specific monitoring for adverse events during PPI therapy.

AB - Proton pump inhibitors (PPIs) are among the most widely used of prescription drugs. They have revolutionized the management of gastroesophageal reflux disease and other acid-related disorders. Although generally safe, concerns about possible adverse effects continue to arise. Some of these, such as gastric neoplasms, are of theoretical concern only and are related to suppression of gastric acid secretion and consequent hypergastrinemia; these have not been encountered in clinical practice despite millions of patient-years of use. Others are more idiosyncratic, unpredictable, and rare. In general, the therapeutic benefits of PPIs outweigh these potential risks. However, it is important that PPIs are only given for appropriate indications and that, whenever possible, they are used in the lowest effective dose. At present, there is no need for specific monitoring for adverse events during PPI therapy.

UR - http://www.scopus.com/inward/record.url?scp=57649133963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649133963&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e31817149bf

DO - 10.1097/MJT.0b013e31817149bf

M3 - Review article

VL - 15

SP - 536

EP - 542

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 6

ER -